✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Sundrug Co Ltd

Common Name
Sundrug
Country
Japan
Sector
Healthcare
Industry
Pharmaceutical Retailers
Employees
7,145
Ticker
9989
Exchange
Japan Exchange Group
Description
Sundrug Co., Ltd. is a prominent player in Japan's pharmaceutical and retail industry, operating a widespread network of drugstores and dispensing pharmacies. The company primarily focuses on providin...

Sundrug's Financial Statements Preview

Below are the financial statements of Sundrug, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in millions of JPY
2024
2023
Net sales
751,777a
690,462a
Cost of sales
-562,457a
-518,516a
Gross profit
189,319a
171,946a
Selling, general and administrative expenses
Provision of allowance for doubtful accounts
-17a
-1a
Provision for retirement benefits for directors (and other officers)
-11a
-7a
Salaries, allowances and bonuses
-54,195a
-49,681a
Retirement benefit expenses
-638a
-638a
Rent expenses
-31,383a
-29,590a
Other
-62,075a
-54,574a
Total selling, general and administrative expenses
-148,323a
-134,493a
Operating profit
40,996a
37,452a
Non-operating income
Interest income
120a
119a
Dividend income
7a
6a
Commission income
91a
74a
Gain on receipt of donated non-current assets
350a
254a
Other
220a
270a
Total non-operating income
791a
725a
Non-operating expenses
Interest expenses
-32a
-36a
Provision of allowance for doubtful accounts
0a
-2a
Other
-26a
-4a
Total non-operating expenses
-59a
-43a
Ordinary profit
41,728a
38,134a
Extraordinary income
Gain on sale of non-current assets
21a
157a
Compensation income
4a
25a
State subsidy
429a
451a
Other
154a
26a
Total extraordinary income
610a
660a
Extraordinary losses
Cancellation penalty
0a
-123a
Loss on sale of non-current assets
0a
-13a
Loss on retirement of non-current assets
-133a
-108a
Loss on cancellation of rental contracts
-9a
-47a
Impairment losses
-481a
-542a
Loss on tax purpose reduction entry of non-current assets
-242a
-214a
Other
-211a
-35a
Total extraordinary losses
-1,078a
-1,084a
Profit before income taxes
41,261a
37,710a
Income taxes - current
-13,130a
-12,988a
Income taxes - deferred
-995a
-980a
Total income taxes
-12,134a
-12,007a
Profit
29,126a
25,703a
Profit attributable to non-controlling interests
0a
0a
Profit attributable to owners of parent
29,126a
25,703a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research

Verified Sources Behind Sundrug’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Sundrug's Integrated Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?